Pyxis Oncology (PYXS) to Release Quarterly Earnings on Tuesday

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.01. The company had revenue of $16.15 million during the quarter. On average, analysts expect Pyxis Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pyxis Oncology Stock Performance

PYXS traded down $0.03 during trading on Friday, reaching $1.06. The stock had a trading volume of 441,657 shares, compared to its average volume of 738,661. The business has a 50-day moving average of $1.05 and a 200-day moving average of $1.72. Pyxis Oncology has a one year low of $0.83 and a one year high of $5.39. The stock has a market cap of $65.66 million, a PE ratio of -1.03 and a beta of 1.15.

Analyst Ratings Changes

A number of brokerages have commented on PYXS. Royal Bank of Canada reiterated an "outperform" rating and set a $8.00 price target on shares of Pyxis Oncology in a research report on Wednesday, March 19th. HC Wainwright reaffirmed a "buy" rating and set a $5.00 target price on shares of Pyxis Oncology in a report on Wednesday, March 19th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Pyxis Oncology presently has an average rating of "Moderate Buy" and a consensus target price of $9.00.

Institutional Trading of Pyxis Oncology

A hedge fund recently raised its stake in Pyxis Oncology stock. Bank of America Corp DE grew its stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) by 20.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 53,745 shares of the company's stock after purchasing an additional 9,062 shares during the period. Bank of America Corp DE owned approximately 0.09% of Pyxis Oncology worth $84,000 as of its most recent SEC filing. 39.09% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.